美国将幽门螺杆菌被列为明确致癌物后，幽门螺杆菌在中国受到了极大的关注。iiMedia Research（艾媒咨询）数据显示，2021年中国幽门螺杆菌检测市场规模73.1亿元，预计2022年将达到86.6亿元。艾媒咨询分析师认为，随着大众的健康意识逐渐加强，幽门螺杆菌自测产品将成为必需品，幽门螺杆菌检测市场发展空间广阔。而幽门螺杆菌自测产品的上市，有助于推动居家检测。(《艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告》完整高清PDF版共23页，可点击文章底部报告下载按钮进行报告下载)
After the United States Department of Health & Human Services listed Helicobacter pylori as a definitive carcinogen, Helicobacter pylori received great attention in China. According to data from iiMedia Research, the market size of Helicobacter pylori testing in China will be 7.31 billion yuan in 2021 and is expected to reach 8.66 billion yuan in 2022. With increasing health awareness, Helicobacter pylori self-test product is necessary for people. The market for Helicobacter pylori self-test product is vast. The launch of Helicobacter pylori self-test products helps to promote home testing.（“iiMedia Report ｜Investigation Report on The Market of Helicobacter Pylori Testing in China in 2022”full version has 23 pages, please click the Browse HD Report button on the right side of the article to browse the report）

本报告研究涉及企业/品牌/案例：老肯医疗，新华医疗，威莱，三友化工；
其他提及企业/品牌：滴露，威露士，蓝月亮，洗得宝，威猛先生，如辉，巨光，海氏海诺，威王，净安，优露清，利尔康，安洁，威洁士，欧洁，仁和，泰和科技，京汉股份，比亚迪，仁瑞生物科技，盘龙药业，东北制药等。

2020年4月28日，全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020年全球消毒杀毒产品市场分析及发展趋势报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据，对全球消毒杀毒产品进行全面分析，并且通过对三友化工、威莱集团（威尔士）、新华医疗和老肯医疗的典型企业案例分析，特别结合新冠疫情影响下消毒杀毒用品的用户调研，判断2020-2021年全球消毒杀毒行业发展趋势。随着经济环境和人民生活水平不断改善，国家对于医疗卫生更加重视，卫生投入不断增加，医疗机构数量显著增长，居民的卫生健康意识也持续提高，从需求端拉动消毒产品行业发展。特别在新冠疫情影响下，消毒杀毒产品的需求量骤升，其中小包装的消杀产品需求量特别大，短期消杀用品存在供需结构矛盾。

In 2020, the national medical institutions and other public places need large-scale, long-term, high-frequency disinfection, in addition, the public awareness of home disinfection has also given birth to a huge demand for disinfection products. According to iiMedia Research, the new crown outbreak in 2020 has had an impact on the purchase of disinfection products by 84% of consumers, with the market value of disinfection products expected to reach 38.26 billion yuan for the full year.

本报告研究涉及企业/品牌/案例：同仁堂，片仔癀，东阿阿胶，太极集团，胡庆余堂，同仁牛黄清心丸，黄芪颗粒，雷氏丹参片，云峰气血口服液，太极五子衍宗丸，太极生力雄丸，仲景左归丸，一笑堂龟甲壳，白云山复方丹参片，天士力养血清脑颗粒，白云山夏桑菊颗粒，白云山板蓝根颗粒

随着居民消费水平的提升和健康保健意识的增强，总体健康需求在扩大，进而推动中医药市场的发展，2018年中国中药材市场规模达1246亿元，同比增长22.40%，预计到2024年，中药材市场规模将达2004亿元。
iiMedia Research（艾媒咨询）调查显示，2019年接近五成受访者购买过中药材，滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛，中医药产业链不断扩展延伸，并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场，建设中药大健康产业，如植物提取物、保健食品、中药化妆品等，已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.

（以下为节选页，完整版共88页）

本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药

国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。

中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。

Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.

本报告研究涉及企业/品牌/案例：天猫医馆，七乐康，京卫大药房，阿里健康大药房,京东大药房,健客, 1药网,360好药,八百方,818医药网,CVS,Walgreens ,RiteAid ,开心人网上药店，药房网，药材买卖网，珍材网，中药材天地网，商康网，科欣医药，医药在线，我的医药网，药品交易网，药品终端网，药师帮，海王晨星，快方送药，药给力，搜药送，药急送，U医U药，叮当送药，健客网上药店，康爱多掌上药店，问药，好药师，111集团，中宏保险，医联，腾讯，仁和药业，浙江扁鹊，漱玉平民，华人健康，一树药业，德生堂

2019中国医药电商主要形成了B2C、B2B、O2O三种模式，B2C模式体量稳定在6%左右，规模呈增长趋势，预计2019年的市场交易额将达到554.6亿元;B2B模式下，西药类产品的需求比例较高，达87.1%，中药材、传统药品和第三方交易等都形成了专属B2B平台;而近几年兴起的O2O模式，主要通过“引流-转化-消费-反馈”等实现盈利，但区域覆盖度和消费者的信任度需要提高。iiMedia Research(艾媒咨询)大数据监测显示，目前1药网、健客网上药店、康爱多掌上药店的的综合实力排行较强。

2019 China's pharmaceutical e-commerce mainly formed three modes of B2C, B2B and O2O. The volume of B2C model is stable at around 6%, and the scale is increasing. It is expected that the market transaction volume in 2019 will reach 55.46 billion yuan; in B2B mode, western medicine The demand ratio of products is relatively high, reaching 87.1%. Chinese herbal medicines, traditional medicines and third-party transactions have formed a proprietary B2B platform. In recent years, the O2O model has emerged mainly through “drainage-conversion-consumption-feedback”. Achieve profitability, but regional coverage and consumer trust need to be improved. iiMedia Research (Ai Media Consulting) big data monitoring shows that the current comprehensive strength of 1 drug network, Jianke online pharmacy, Kang Aiduo pharmacy is strong.

本报告涉及的案例/品牌/企业：美团买药，叮当快药

在众多社会服务中，夜间用药成为人们最关注的夜间社会服务之一，近年来，各地相关行政管理机构也陆续出台相关扶持政策，鼓励商家上线夜间送药平台、发展24小时药店，提供夜间送药服务，推动解决“夜间买药难”问题。近日，iiMedia Research(艾媒咨询)最新发布《2021年中国夜间用药年度观察报告》，基于2021年初至2021年末的监测数据，对中国夜间用药市场持续追踪。报告显示，年初有61.2%的用户夜间生病选择忍，而年底这一数字降至52.1%，据推算年末夜间用药受益群体新增约4000万人。报告指出，日渐成熟的中国外卖送药平台，成为解决夜间用药的重要参与者。通过一年的发展，在美团买药“小黄灯”计划等24小时药店惠民工程的推动下，线上24小时药店数量增加、夜间买药配送速度更快、服务保障更加成熟，用户知晓度有了较大提升，夜间买药难的问题得到有效缓解。
Among many social services，night medication has become one of the night social services that people pay most attention to. In recent years，relevant administrative agencies around the country have also successively issued relevant support policies to encourage businesses to launch night medication delivery platforms，develop 24-hour pharmacies，provide night medication delivery services， and promote the solution of the problem of "difficulty in buying drugs at night". Recently， iiMedia Research released the annual observation report on nighttime medication in China in 2021，which continuously tracks China's nighttime medication market based on the monitoring data from the beginning of 2021 to the end of 2021. The report shows that at the beginning of the year， 61.2% of users chose to tolerate illness at night，while at the end of the year，the figure fell to 52.1%. It is estimated that about 40 million people will benefit from night medication at the end of the year.The report points out that the increasingly mature Chinese takeout delivery platform has become an important participant in solving the problem of night medication. Through one year's development，driven by the 24-hour pharmacy benefit project such as the "small yellow light" plan of meituan drug purchase， the number of online 24-hour pharmacies has increased，the speed of drug purchase and distribution at night is faster，the service guarantee is more mature，the user awareness has been greatly improved，and the problem of difficult drug purchase at night has been effectively alleviated.

本报告研究涉及企业/品牌/案例：同仁堂、香雪制药、白云山。

数据显示，2020年第三季度，中药材价格指数迎来上涨周期。艾媒咨询分析师认为，受动物类等少数品种拉动影响，预计2020年10-11月中药材指数会持续走高，但是在12月维稳。据调查，绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营，采取减少压货炒作等经营方式。因而，预计中药材市场在2020年末旺季会有一波行情的走高，但随着旺季结束，明年年初的价格会重新回落，随着疫情的常态化，中药材市场行情预期会呈周期性波动的态势。

Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation.

本报告研究涉及企业/品牌/案例：华夏源、复星医药。

中国细胞生物产业类型呈现多样化趋势，细胞生物临床研究不断深化，伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成，生态圈的完善将在很大限度上推动产业快速发展。数据显示，中国细胞治疗企业融资金额不断增加，从2014年的0.2亿元增长至2019年的28.9亿元。其中，2018年中国细胞治疗企业融资额同比增长706.8%，呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇，同时也有挑战并存。后续产业的发展，将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局，企业也应积极开展生态合作以及更为密切关注市场需求动向，将疗法和新一代医疗创新技术深度融合，实现市场产品多元化与差异化，并推出独特性的精准治疗，从而最大限度地释放产业价值。

The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value.

本报告研究涉及企业/品牌/案例：云南白药，天士力。

数据显示，2020年4-5月中药材价格指数小幅下降，行情总体较为震荡。艾媒咨询分析师认为，自第二季度起中药材基本不受新冠肺炎疫情影响，市场秩序趋于稳定，但需求仍然不足，中药材基本以减产居多，减产的信号给予商家部分信心，一旦消费情况好转，中药材价格会重新上涨，因此商家谨慎投资与积极备货双管齐下，导致第二季度中药材大盘指数震荡。

Data show that the price index of Chinese medicinal materials declined slightly from April to May 2020, and the market was generally volatile. iiMedia Research believe that since the second quarter, Chinese herbal medicines have basically not been affected by the new coronary pneumonia epidemic. The market order has stabilized, but demand is still insufficient. Basically, Chinese herbal medicines basically reduce production. The signal of reduced production gives businesses some confidence. Once consumed The situation improves, and the prices of Chinese herbal medicines will rise again. Therefore, merchants' cautious investment and active inventory preparation have taken two measures, leading to the second quarter Chinese herbal medicines market index shock.

本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业

随着生物医药技术不断突破，中国生物医药产业快速发展，2018年，单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元，实现同比增长。iiMedia Research(艾媒咨询)监测发现，生物医药产业网络言值指数为49.7，网民评价态度偏向正面，上海网民对生物医药产业的关注度最高。未来，随着中国生物医药行业上市公司数量增多，行业与企业间竞争将更加激烈。

The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.